1
|
Huben RP, Mounzer AM and Murphy GP: Tumor
grade and stage as prognostic variables in upper tract urothelial
tumors. Cancer. 62:2016–2020. 1988. View Article : Google Scholar : PubMed/NCBI
|
2
|
Margulis V, Shariat SF, Matin SF, Kamat
AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD and Wood CG;
Upper Tract Urothelial Carcinoma Collaboration The Upper Tract
Urothelial Carcinoma Collaboration, : Outcomes of radical
nephroureterectomy: A series from the upper tract urothelial
carcinoma collaboration. Cancer. 115:1224–1233. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Califano G, Ouzaid I, Verze P, Hermieu JF,
Mirone V and Xylinas E: Immune checkpoint inhibition in upper tract
urothelial carcinoma. World J Urol. 39:1357–1367. 2021. View Article : Google Scholar : PubMed/NCBI
|
4
|
Qin S, Xu L, Yi M, Yu S, Wu K and Luo S:
Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol
Cancer. 18:1552019. View Article : Google Scholar : PubMed/NCBI
|
5
|
Anderson AC, Joller N and Kuchroo VK:
Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized
functions in immune regulation. Immunity. 44:989–1004. 2016.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Stanietsky N, Rovis TL, Glasner A, Seidel
E, Tsukerman P, Yamin R, Enk J, Jonjic S and Mandelboim O: Mouse
TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur
J Immunol. 43:2138–2150. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Nishiwada S, Sho M, Yasuda S, Shimada K,
Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N and Nakajima
Y: Clinical significance of CD155 expression in human pancreatic
cancer. Anticancer Res. 35:2287–2297. 2015.PubMed/NCBI
|
8
|
Zhang J, Zhu Y, Wang Q, Kong Y, Sheng H,
Guo J, Xu J and Dai B: Poliovirus receptor CD155 is up-regulated in
muscle-invasive bladder cancer and predicts poor prognosis. Urol
Oncol. 38:41.e11–41.e18. 2020. View Article : Google Scholar : PubMed/NCBI
|
9
|
Xu Y, Cui G, Jiang Z, Li N and Zhang X:
Survival analysis with regard to PD-L1 and CD155 expression in
human small cell lung cancer and a comparison with associated
receptors. Oncol Lett. 17:2960–2968. 2019.PubMed/NCBI
|
10
|
Atsumi S, Matsumine A, Toyoda H, Niimi R,
Iino T and Sudo A: Prognostic significance of CD155 mRNA expression
in soft tissue sarcomas. Oncol Lett. 5:1771–1776. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Sloan KE, Eustace BK, Stewart JK,
Zehetmeier C, Torella C, Simeone M, Roy JE, Unger C, Louis DN, Ilag
LL and Jay DG: CD155/PVR plays a key role in cell motility during
tumor cell invasion and migration. BMC Cancer. 4:732004. View Article : Google Scholar : PubMed/NCBI
|
12
|
Chauvin JM and Zarour HM: TIGIT in cancer
immunotherapy. J Immunother Cancer. 8:e0009572020. View Article : Google Scholar : PubMed/NCBI
|
13
|
Sanchez-Correa B, Valhondo I, Hassouneh F,
Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés
I, Durán E, et al: DNAM-1 and the TIGIT/PVRIG/TACTILE axis: Novel
immune checkpoints for natural killer cell-based cancer
immunotherapy. Cancers (Basel). 11:8772019. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kim YS, Kim K, Kwon GY, Lee SJ and Park
SH: Fibroblast growth factor receptor 3 (FGFR3) aberrations in
muscle-invasive urothelial carcinoma. BMC Urol. 18:682018.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
16
|
Wang L, Gong Y, Saci A, Szabo PM, Martini
A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, et
al: Fibroblast growth factor receptor 3 alterations and response to
PD-1/PD-L1 blockade in patients with metastatic urothelial cancer.
Eur Urol. 76:599–603. 2019. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kacew A and Sweis RF: FGFR3 alterations in
the era of immunotherapy for urothelial bladder cancer. Front
Immunol. 11:5752582020. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chen S, Zhang N, Shao J, Wang T and Wang
X: Multi-omics perspective on the tumor microenvironment based on
PD-L1 and CD8 T-Cell infiltration in urothelial cancer. J Cancer.
10:697–707. 2019. View Article : Google Scholar : PubMed/NCBI
|
19
|
Moch H, Humphrey PA, Ulbright TM and
Reuter VE: WHO classification of tumours of the urinary system and
male genital organs. WHO Classification of Tumours. 8. 4th edition.
International Agency for Research on Cancer; Lyon: 2016
|
20
|
Brierley J, Gospodarowicz MK and Wittekind
C: TNM classification of malignant tumours. 8th edition. John Wiley
& Sons Inc.; Hoboken, NJ: 2017
|
21
|
Ikeda J, Ohe C, Yoshida T, Kuroda N, Saito
R, Kinoshita H, Tsuta K and Matsuda T: Comprehensive pathological
assessment of histological subtypes, molecular subtypes based on
immunohistochemistry, and tumor-associated immune cell status in
muscle-invasive bladder cancer. Pathol Int. 71:173–182. 2021.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Molfetta R, Zitti B, Lecce M, Milito ND,
Stabile H, Fionda C, Cippitelli M, Gismondi A, Santoni A and
Paolini R: CD155: A multi-functional molecule in tumor progression.
Int J Mol Sci. 21:9222020. View Article : Google Scholar : PubMed/NCBI
|
24
|
Bowers JR, Readler JM, Sharma P and
Excoffon KJDA: Poliovirus receptor: More than a simple viral
receptor. Virus Res. 242:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
25
|
Rikitake Y, Mandai K and Takai Y: The role
of nectins in different types of cell-cell adhesion. J Cell Sci.
125:3713–3722. 2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Gao J, Zheng Q, Xin N, Wang W and Zhao C:
CD155, an onco-immunologic molecule in human tumors. Cancer Sci.
108:1934–1938. 2017. View Article : Google Scholar : PubMed/NCBI
|
27
|
Shariat SF, Youssef RF, Gupta A, Chade DC,
Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R and
Lotan Y: Association of angiogenesis related markers with bladder
cancer outcomes and other molecular markers. J Urol. 183:1744–1750.
2010. View Article : Google Scholar : PubMed/NCBI
|
28
|
Kinugasa M, Amano H, Satomi-Kobayashi S,
Nakayama K, Miyata M, Kubo Y, Nagamatsu Y, Kurogane Y, Kureha F,
Yamana S, et al: Necl-5/poliovirus receptor interacts with VEGFR2
and regulates VEGF-induced angiogenesis. Circ Res. 110:716–726.
2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Luke JJ, Bao R, Sweis RF, Spranger S and
Gajewski TF: WNT/β-catenin pathway activation correlates with
immune exclusion across human cancers. Clin Cancer Res.
25:3074–3083. 2019. View Article : Google Scholar : PubMed/NCBI
|
30
|
Xue G, Romano E, Massi D and Mandalà M:
Wnt/β-catenin signaling in melanoma: Preclinical rationale and
novel therapeutic insights. Cancer Treat Rev. 49:1–12. 2016.
View Article : Google Scholar : PubMed/NCBI
|
31
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Sweis RF, Spranger S, Bao R, Paner GP,
Stadler WM, Steinberg G and Gajewski TF: Molecular drivers of the
non-T-cell-inflamed tumor microenvironment in urothelial bladder
cancer. Cancer Immunol Res. 4:563–568. 2016. View Article : Google Scholar : PubMed/NCBI
|
33
|
Buchtova M, Oralova V, Aklian A, Masek J,
Vesela I, Ouyang Z, Obadalova T, Konecna Z, Spoustova T,
Pospisilova T, et al: Fibroblast growth factor and canonical
WNT/β-catenin signaling cooperate in suppression of chondrocyte
differentiation in experimental models of FGFR signaling in
cartilage. Biochim Biophys Acta. 1852:839–850. 2015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Xiao JF, Caliri AW, Duex JE and
Theodorescu D: Targetable pathways in advanced bladder cancer: FGFR
signaling. Cancers (Basel). 13:48912021. View Article : Google Scholar : PubMed/NCBI
|